| Alpha-1 Antitrypsin Disease Cohort: Longitudinal Biomarker Study of Disease (NCT05297812) | Columbia University | 2022-03-23 |
| Functional and Structural Lung Imaging in Chronic Obstructive Pulmonary Disease (NCT04966221) | University of Nottingham | 2022-01-01 |
| An Extension Study of Belcesiran in Patients With Alpha-1 Antitrypsin Deficiency Associated Liver Disease (AATLD) (NCT05146882) | Dicerna Pharmaceuticals, Inc., a Novo Nordisk company | 2021-12-01 |
| A Study of Belcesiran in Patients With AATLD (NCT04764448) | Dicerna Pharmaceuticals, Inc., a Novo Nordisk company | 2021-02-12 |
| Evaluation of the Efficacy and Safety of VX-814 in Subjects With the PiZZ Genotype (NCT04167345) | Vertex Pharmaceuticals Incorporated | 2020-01-13 |
| Phase III, Efficacy and Safety of "Kamada-AAT for Inhalation" (NCT04204252) | Kamada, Ltd. | 2019-11-25 |
| Study of DCR-A1AT in Healthy Adult Volunteers (NCT04174118) | Dicerna Pharmaceuticals, Inc., a Novo Nordisk company | 2019-10-24 |
| Respreeza® Self-administration and Learning Program (AmAREtTI Study) (NCT04262284) | CSL Behring | 2019-10-18 |
| Safety, Tolerability and Pharmacodynamic Effect of Fazirsiran (TAK-999, ARO-AAT) (NCT03945292) | Arrowhead Pharmaceuticals | 2019-08-07 |
| Phase 1 Study to Assess the Safety, PK and PD of INBRX-101 in Adults With Alpha-1 Antitrypsin Deficiency (NCT03815396) | Inhibrx Biosciences, Inc | 2019-07-19 |
| Alpha-1 Research Registry (NCT04157049) | Alpha-1 Foundation | 2019-06-20 |
| Effects of Different Exercise Training Modalities in Alpha-1 Antitrypsin Deficiency Patients (NCT03802357) | Schön Klinik Berchtesgadener Land | 2019-01-10 |
| Long-Term Follow-up Study of ADVM-043 (NCT03804021) | Adverum Biotechnologies, Inc. | 2018-12-27 |
| A 12-week Study Treating Participants Who Have alpha1-antitrypsin-related COPD With Alvelestat (MPH966) or Placebo. (NCT03636347) | Mereo BioPharma | 2018-10-29 |
| Study Comparing Weekly Intravenous Administration of OctaAlpha1 With a Marketed Preparation Glassia® in Subjects With Alpha-1-antitrypsin Deficiency (NCT03385395) | Octapharma | 2018-07-01 |
| Exploring the Utility of Hyperpolarized 129Xe MRI in Healthy Volunteers and Patients With Lung Disease (NCT03455686) | McMaster University | 2018-04-19 |
| Study of ARO-AAT in Normal Adult Volunteers (NCT03362242) | Arrowhead Pharmaceuticals | 2018-03-12 |
| Czech AATD Registry (NCT05178277) | Thomayer University Hospital | 2018-01-01 |
| Safety Dose Finding Study of ADVM-043 Gene Therapy to Treat Alpha-1 Antitrypsin (A1AT) Deficiency (NCT02168686) | Adverum Biotechnologies, Inc. | 2017-11-28 |
| The Effects of Discontinuation of Vitamin K Antagonists on the Rate of Elastin Degradation (NCT03285100) | Canisius-Wilhelmina Hospital | 2017-10-31 |
| Efficacy/Safety of HA Inhalation Solution for Hereditary Emphysema in Patients With Alpha-1 Antitrypsin Deficiency (NCT03114020) | Gerard Turino | 2017-03-22 |
| Targeting Pulmonary Perfusion in Alpha-1 Antitrypsin Deficiency (NCT03008915) | Columbia University | 2017-01-01 |
| The Impact of Delayed Diagnosis of Alpha-1 Antitrypsin Deficiency (NCT03039335) | Biocerna LLC | 2016-12-15 |
| Safety, Tolerability and Effect of ARC-AAT Injection on Circulating and Intrahepatic Alpha-1 Antitrypsin Levels (NCT02900183) | Arrowhead Pharmaceuticals | 2016-10-01 |
| Epigenetic Regulation of Immunity in Alpha-1 Anti-trypsin Deficiency (NCT02691611) | National Jewish Health | 2015-12-01 |
| Environment Effect on Six-Minute Walk Test Performance (NCT02502201) | University of Florida | 2015-10-01 |
| Microbioma in Sputa From COPD With Alpha-1 Antitrypsin Deficiency (NCT02547532) | Fondazione Salvatore Maugeri | 2015-09-01 |
| A Study of ARC-AAT in Healthy Volunteer Subjects and Patients With Alpha-1 Antitrypsin Deficiency (AATD) (NCT02363946) | Arrowhead Pharmaceuticals | 2015-02-01 |
| Alpha-1 Carrier Genomics Study (NCT02810327) | Medical University of South Carolina | 2015-02-01 |
| Lung Volume Reduction Coils for Emphysema in Alpha-1 Antitrypsin Deficiency (NCT02273349) | University Hospital, Saarland | 2014-10-01 |
| Phase II, Safety and Efficacy Study of Kamada-alpha-1-antitrypsin (AAT) for Inhalation" (NCT02001688) | Kamada, Ltd. | 2014-04-01 |
| Alpha-1 Antitrypsin Deficiency Adult Liver Study (NCT02014415) | St. Louis University | 2013-12-01 |
| Ex-vivo Perfusion and Ventilation of Lungs Recovered From Non-Heart-Beating Donors to Assess Transplant Suitability (NCT01615484) | University of North Carolina, Chapel Hill | 2013-09-01 |
| Genomic Research in Alpha-1 Antitrypsin Deficiency (NCT01832220) | University of Pittsburgh | 2013-05-01 |
| Effect of Double Dose of Alpha 1-antitrypsin Augmentation Therapy on Lung Inflammation. (NCT01669421) | Michael Campos, MD | 2012-07-01 |
| Carbamazepine in Severe Liver Disease Due to Alpha-1 Antitrypsin Deficiency (NCT01379469) | Washington University School of Medicine | 2012-01-01 |
| Phase 2 Study of Ex-vivo Perfusion and Ventilation of Lungs to Assess Transplant Suitability (NCT01241942) | University of North Carolina, Chapel Hill | 2010-12-01 |
| Safety & Efficacy Study of rAAV1-CB-hAAT for Alpha-1 Antitrypsin Deficiency (NCT01054339) | Beacon Therapeutics | 2010-06-01 |
| Effects of Exercise Training in Chronic Obstructive Pulmonary Disease Versus Alpha-1-Antitrypsin-deficiency-patients (NCT01380626) | Schön Klinik Berchtesgadener Land | 2010-02-01 |
| Prevalence of Alpha-1 Antitrypsin Deficiency in Chronic Obstructive Pulmonary Disease (COPD) (NCT01419158) | Alpha-1 Foundation | 2008-01-01 |
| Longitudinal Study of Genetic Causes of Intrahepatic Cholestasis (LOGIC) (NCT00571272) | Arbor Research Collaborative for Health | 2007-11-30 |
| Lung Disease and Its Affect on the Work of White Blood Cells in the Lungs (NCT01851642) | University of Florida | 2007-08-09 |
| The Use of High Resolution Chest Computed Tomography in Alpha-1 Antitrypsin Deficiency (NCT00532805) | Medical University of South Carolina | 2007-08-01 |
| Phase II/III Study of an Alpha-1 Proteinase Inhibitor (Kamada-API) in Individuals With Alpha-1 Antitrypsin Deficiency (NCT00460096) | Kamada, Ltd. | 2007-03-01 |
| Efficacy and Safety Study of Augmentation Therapy With ARALAST Fraction IV-1 (Human Alpha 1 - Proteinase Inhibitor) (NCT00396006) | Baxalta now part of Shire | 2006-10-27 |
| The Safety and Tolerability of Alpha-1 Modified Process (MP) In Subjects With Alpha-1-antitrypsin (AAT) Deficiency (NCT00301366) | Grifols Therapeutics LLC | 2006-06-01 |
| Comparison of Pharmacokinetic, Safety, Tolerability of Alpha-1 MP and Prolastin In Alpha1-antitrypsin Deficient Adults (NCT00295061) | Grifols Therapeutics LLC | 2006-05-01 |
| Experimental Gene Transfer Procedure to Treat Alpha 1-Antitrypsin (AAT) Deficiency (NCT00430768) | University of Massachusetts, Worcester | 2006-02-01 |
| Pharmacokinetic Study of ARALAST (Human Alpha1- PI) (NCT00242385) | Baxalta now part of Shire | 2005-12-20 |
| Management of Patients With Alpha-1 Antitrypsin Deficiency Associated Emphysema (NCT00700934) | Assistance Publique - Hôpitaux de Paris | 2005-02-01 |
| Experimental Gene Transfer Procedure to Treat Alpha 1-Antitrypsin Deficiency (NCT00377416) | University of Massachusetts, Worcester | 2004-03-01 |
| Alpha-1-Antitrypsin (AAT) To Treat Emphysema In AAT-Deficient Patients (EXACTLE) (NCT00263887) | Grifols Therapeutics LLC | 2003-12-01 |
| Alpha-1 Foundation DNA and Tissue Bank (NCT00884455) | University of Florida | 2002-12-01 |
| 4-PBA: Will it Increase the Level of Alpha 1-Antitrypsin(AAT) in Persons With AAT Deficiency? (NCT00067756) | University of Florida | 2001-11-01 |
| Alpha-1 Foundation Research Registry (NCT00499941) | Medical University of South Carolina | 2000-04-01 |
| Study of Genotype and Phenotype in Patients With Alpha 1-Antitrypsin Deficiency (NCT00005098) | National Center for Research Resources (NCRR) | 1999-03-01 |
| Characterization of the Pathobiology of Early Lung Destruction in Alpha 1-Antitrypsin Deficient Individuals (NCT00001462) | National Heart, Lung, and Blood Institute (NHLBI) | 1995-05-01 |
| Alpha1-antitrypsin Deficiency Registry (NCT00005292) | National Heart, Lung, and Blood Institute (NHLBI) | 1988-09-01 |
| Early Access Program Using Alpha 1 Antitrypsin Infusion for Patients With Steroid Refractory Acute GvHD After Hematopoietic Stem Cell Transplantation (HSCT) (NCT03172455) | Impatients N.V. trading as myTomorrows | |